Drugs / PEG-rASNase
Trials 1 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1/2 | NCT01251809 | Jan 2011 → Oct 2012 | acute lymphoblastic leukemia | medac GmbH | Terminated | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | PEG-rASNase | ClinicalTrials.gov intervention name — accepted as the source's own label NCT01251809 ↗ |
| Known as | pegylated recombinant asparaginase | “This is an assessment of efficacy and safety of three different doses of pegylated recombinant asparaginase (PEG-rASNase) in comparison to Oncaspar® during treatment of adults...” NCT01251809 ↗ |